Fossils found in North America reveal new species of 'very odd' sea monster: Scientists
A prehistoric sea monster never-before-known to man was hunting prey in North America 85 million years ago, fossils found decades ago in Canada reveal.
The first set of fossils, found in 1988 along the Puntledge River on Vancouver Island, were determined to belong to elasmosaurs, a genus of plesiosaur that lived in North America during the Late Cretaceous period, about 80.6 to 77 million years ago, according to the paper, published in the Journal of Systematic Palaeontology. Additional fossils found since include an isolated right humerus and a well-preserved juvenile skeleton comprising of a thorax, girdles and limbs, according to the study.
MORE: Evidence of 30-foot ancient sea monster found in Mississippi
But they have now been formally identified to belong to a "very odd" new genus of sea monster called Traskasaura sandrae, the researchers said.
The long-necked creature likely measured about 39 feet and had heavy, sharp teeth that were "ideal for crushing" ammonite shells, according to paleontologists. Dozens of well-preserved cervical vertebrae indicate at least 50 bones in the neck -- likely more, the researchers said.
T. sandrae also had a "strange mix" of primitive and derived traits, unlike any other elasmosaur. Its unique adaptations allowed it to hunt prey from above -- the first of the plesiosaur taxa to do so, the paper states.
Prey was likely abundant in the region at the time, the scientists said.
"It has a very odd mix of primitive and derived traits," O'Keefe said. "The shoulder, in particular, is unlike any other plesiosaur I have ever seen, and I have seen a few."
MORE: Underwater camera captures elusive tentacled creature 3 miles below ocean surface
When lead author F. Robin O'Keefe first saw the fossils and realized they belonged to an entirely new taxon, he hypothesized that they may be related to the plesiosaurs from Antarctica, he said in a statement. But it is "a strange, convergently evolved, fascinating beast," O'Keefe said.
"The fossil record is full of surprises," O'Keefe said. "It is always gratifying to discover something unexpected."
The fossils are among the most famous in the country. In 2002, they were adopted by the Province of British Columbia and declared the official fossil emblem of British Columbia.
"Plesiosaur fossils have been known for decades in British Columbia," O'Keefe said. "However, the identity of the animal that left the fossils has remained a mystery, even as it were declared BC's provincial fossil in 2023. Our new research, published today, finally solves this mystery."
MORE: What paleontologists learned from fossils of a 3-eyed predator that lived 500 million years ago
Paleontologists were reluctant at first to erect a new genus based solely on the adult skeleton of the elasmosaur. But a new 'excellently preserved' partial skeleton enabled this latest international team of scientists from Canada, Chile and the U.S. to eventually identify the new genus and species.
The genus name Traskasaura was given in honor of Courtenay, British Columbia, where the researchers who discovered the original specimen in 1988 were based. The species name sandrae honors Sandra Lee O'Keefe, a member of the team of researchers who identified the fossils in 2002.
They are currently on display at the Courtenay and District Museum and Palaeontology Centre in Courtenay, British Columbia.
Fossils found in North America reveal new species of 'very odd' sea monster: Scientists originally appeared on abcnews.go.com
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Cero announces two granted U.S. patents, European patent application allowance
CERo Therapeutics (CERO) Holdings announces two previously announced U.S. patent applications have been granted by the U.S. Patent and Trademark Office, and one European patent application has been allowed by the European Patent Office, all of which significantly expand the Company's intellectual property portfolio. The USPTO granted U.S. Patent No. 12,291,557, titled, 'CHIMERIC TIM4 RECEPTORS AND USES THEREOF' on May 6, 2025. The granted claims cover certain design aspects of CER-1236, the Company's lead compound. This patent provides composition of matter protection for a chimeric TIM4 receptor comprising a TIM4 binding domain and canonical T cell signaling domains. Additionally, the European Patent Office has allowed European Patent Application No. 1882166.7 titled, 'CHIMERIC ENGULFMENT RECEPTOR MOLECULES AND METHODS OF USE' on May 16, 2025. The allowed claims encompass a chimeric engulfment receptor comprising a TIM4 binding domain and TLR2 signaling domain. The allowance of this European patent application expands protection of additional design aspects of CER-1236, which have already been granted in the U.S., Japan, and China. Finally, the USPTO granted U.S. Patent No. 12,303,551, titled, 'CELLULAR IMMUNOTHERAPY COMPOSITIONS AND USES THEREOF,' on May 20, 2025. This patent provides coverage for combination cellular immunotherapy compositions and methods of use for CER-1236. The patent covers combination of a chimeric engulfment receptor CD4+ T cell with a chimeric antigen receptor CD8+ T cell or T cell receptor CD8+ T cell, and their use to treat cancer. This type of combination therapy could be an exciting avenue to complement the CER-T cell technology with other powerful anti-cancer therapies. CERo's intellectual property portfolio now includes 9 total patent families with protection out to 2042 in the United States. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on CERO: Disclaimer & DisclosureReport an Issue Promising Developments in CERo Therapeutics' Novel AML Therapy Underpin Buy Rating Cero Therapeutics doses first patient with CER-1236 in Phase 1 trial Cero Therapeutics downgraded to Hold from Buy at D. Boral Capital CERo Therapeutics Approves Key Proposals at Annual Meeting Maxim starts Cero Therapeutics at Buy, positive on its novel t-cell therapy


Android Authority
5 hours ago
- Android Authority
Samsung is now bringing One UI 7 to the Galaxy A54 in the US
Robert Triggs / Android Authority Galaxy A54 5G TL;DR The One UI 7 update is now available to many Galaxy A54 owners in the US. Users on AT&T, Cricket Wireless, T-Mobile, and Tracfone are reporting that they've received the update. TL;DR 3 The Samsung Galaxy A54 is the most recent Galaxy A50 series smartphone in the US, as the Galaxy A55 skipped the region, and the Galaxy A56 is coming stateside later this year. Fortunately, there's good news if you've got a Galaxy A54 in the US as it's now getting One UI 7. SamMobile reports that the update is now available to some Galaxy A54 owners in the US. It looks like this update is only available to users on Metro PCS, T-Mobile, and US Cellular. This release was corroborated by several users on Reddit (1, 2, 3) and Twitter. The Reddit users added that they were on AT&T, Cricket Wireless, T-Mobile and Tracfone. We're guessing you might have to wait a while to get the update if you're on another carrier. In any event, One UI 7 on the Galaxy A54 weighs in at over 3GB and brings an overhauled visual experience. These visual changes include a redesigned camera app and new icons. Samsung's update also offers the Now Bar feature, along with improved widget customization, and live notifications. News of the update's availability also comes a short while after Samsung kicked off the One UI 8 beta program. This new update is scheduled to arrive in the summer, but we're guessing Galaxy A series owners will have to wait a few months longer. Got a tip? Talk to us! Email our staff at Email our staff at news@ . You can stay anonymous or get credit for the info, it's your choice.
Yahoo
5 hours ago
- Yahoo
Anixa Biosciences' Breast Cancer Vaccine Featured in NewsNation Interview
SAN JOSE, Calif., June 3, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its CEO, Dr. Amit Kumar, was interviewed on NewsNation's "Elizabeth Vargas Reports" to discuss Anixa's breast cancer vaccine. The segment highlighted the potential of Anixa's vaccine to revolutionize the treatment and prevention of breast cancer. Anixa's breast cancer vaccine is designed to train the immune system to recognize and eliminate cancerous cells before they can develop into invasive tumors. The vaccine targets a lactation protein, α-lactalbumin, which is only expressed in the breast when a woman is lactating but not at other times in her life or in other tissues. However, when a woman develops breast cancer many of the malignant cells will express α-lactalbumin. Activating the immune system, through vaccination, to direct cytotoxic T cells to the tumor cell expressing this protein may provide preemptive immune protection against emerging breast tumors that express α-lactalbumin. "We are pleased to have our breast cancer vaccine featured on NewsNation's 'Elizabeth Vargas Reports,' as this national exposure brings greater awareness to the importance of preventative cancer immunotherapy," said Dr. Kumar. "We believe we have made significant progress in the development of this vaccine, having recently completed enrollment in the Phase 1 clinical trial. We look forward to the next stage of development and are optimistic about the impact this vaccine could have in the treatment and prevention of breast cancer." The NewsNation "Elizabeth Vargas Reports" interview can be accessed here: About Anixa Biosciences, Inc. Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit or follow Anixa on Twitter, LinkedIn, Facebook and YouTube. Forward-Looking StatementsStatements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release. Contact:Mike CatelaniPresident, COO & CFOmcatelani@ View original content to download multimedia: SOURCE Anixa Biosciences, Inc. Error in retrieving data Sign in to access your portfolio